Stockscreener 앱 받기
3.90
0.26%
-0.00
전일 마감가:
$3.90
열려 있는:
$3.84
하루 거래량:
1,522
Relative Volume:
0.07
시가총액:
$10.73M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+14.05%
1개월 성능:
+6.28%
6개월 성능:
+35.54%
1년 성능:
+0.00%
1일 변동 폭
$3.76
$3.84
1주일 범위
$3.37
$3.90
52주 변동 폭
$1.96
$6.60
Cosciens Biopharma Inc Stock (CSCI) Company Profile
CSCI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CSCI
Cosciens Biopharma Inc
|
3.80 | 10.73M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
261.57 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.73 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.365 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
85.51 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
496.68 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Cosciens Biopharma Inc 주식(CSCI)의 최신 뉴스
COSCIENS Biopharma reconstitutes board - MSN
COSCIENS BiopharmaEnters Resolution Agreement With Goodwood, Goodwood Fund, And Puccetti Funds Management - marketscreener.com
COSCIENS Biopharma Schedules Virtual Annual Meeting for June 30, 2025 - TipRanks
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Share - GuruFocus
Cosciens Biopharma Brief: Entering Into a Resolution Agreement With Goodwood Inc. As Co Reconstitutes Board for Benefit of Shareholders - marketscreener.com
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders - Yahoo Finance
Cosciens Biopharma announces receipt of Goodwood intended director nominations - Yahoo Finance
COSCIENS Biopharma Receives Director Nominations Ahead of Shareholder Meeting - TipRanks
COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Directo - GuruFocus
COSCIENS Biopharma Receives Director Nominations from Goodwood - TipRanks
COSCIENS Biopharma Inc. Acknowledges Director Nominations from Goodwood Fund Ahead of Annual Shareholder Meeting - Nasdaq
COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders - The Manila Times
Cosciens Biopharma Brief: Acknowledging Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders - marketscreener.com
Goodwood Seeks Board Overhaul At Cosciens Biopharma - Finimize
Goodwood to Nominate New Directors for COSCIENS Biopharma Inc. - The Globe and Mail
Goodwood To Nominate New Directors For COSCIENS Biopharma Inc. - Barchart.com
Databricks Announces 2025 Data + AI Summit Keynote Lineup and Data Intelligence Programming - The Globe and Mail
COSCIENS Biopharma Reports Q1 2025 Results and Updates - TipRanks
COSCIENS Biopharma reports key corporate updates By Investing.com - Investing.com India
COSCIENS Biopharma reports key corporate updates - Investing.com
COSCIENS Biopharma Completes Merger with Ceapro and Restructures Governance - TipRanks
Waverley Pharma: Top 10 Undervalued Biotechnology Industry Stocks (WAVE) - The Globe and Mail
COSCIENS Biopharma: Q1 Earnings Snapshot - CT Insider
COSCIENS Biopharma reports Q1 2025 results, updates strategy By Investing.com - Investing.com Nigeria
COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Res - GuruFocus
COSCIENS Biopharma reports Q1 2025 results, updates strategy - Investing.com
COSCIENS Biopharma Reports Q1 2025 Results and Strategic Updates - TipRanks
COSCIENS Biopharma Reports Q1 2025 Financial Results Amid Strategic Shifts - TipRanks
Cosciens Biopharma Brief: Appointing Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer - marketscreener.com
Cosciens Biopharma Brief: Company Says Ended Quarter with US$13.8 Million in Cash - marketscreener.com
Cosciens Biopharma Brief: Reported a Q1 Consolidated Net Loss of US$3.7 Million, or $1.16 Loss Per Common Share - marketscreener.com
COSCIENS Biopharma Inc. Transitions to Pure-Play Natural Products Company, Announces Phase 2 Clinical Trial Advancements and New CEO Appointment - Nasdaq
COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update - Yahoo Finance
COSCIENS Biopharma Inc. Reports Transformative Year - TipRanks
COSCIENS Biopharma Sets Date for Annual Meeting Amid Strategic Shifts - TipRanks
Fennec Pharmaceuticals: Top 10 Undervalued Biotechnology Industry Stocks (FRX) - The Globe and Mail
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
COSCIENS Biopharma appoints Anna Biehn as new CEO amid leadership change - N24.com.tr
COSCIENS Biopharma Inc. Appoints Global Consumer Products and Bi - GuruFocus
COSCIENS Biopharma (CSCI) Names Anna Biehn as New CEO | CSCI Sto - GuruFocus
COSCIENS Biopharma names new CEO Anna Biehn By Investing.com - Investing.com Canada
COSCIENS Biopharma names new CEO Anna Biehn - Investing.com Australia
COSCIENS Biopharma names Anna Biehn as new CEO By Investing.com - Investing.com South Africa
COSCIENS Biopharma Full Year 2024 Earnings: US$5.93 loss per share (vs US$1.89 loss in FY 2023) - simplywall.st
COSCIENS Biopharma names Anna Biehn as new CEO - Investing.com Australia
Cosciens Biopharma appoints Biehn as CEO - TipRanks
COSCIENS Biopharma Appoints Anna Biehn as New CEO to Drive Growth in Natural-Based Products - TipRanks
Cosciens Biopharma Inc (CSCI) 재무 분석
Cosciens Biopharma Inc (CSCI)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.87%
0.19%
자본화:
|
볼륨(24시간):